InfuSystem Holdings, Inc
For the period ended Sep 30, 2025. Filed Nov 4, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 4, 2025
INFU$15.28+4.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
-Unaudited Condensed Consolidated Statements of Cash Flows for the
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
| Nine Months Ended September 30, | ||
|---|---|---|
| (in thousands) | 2025 | 2024 |
| OPERATING ACTIVITIES | ||
| Net income | $4,591 | $1,412 |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||
| Provision for doubtful accounts | 102 | (141) |
| Depreciation | 9,236 | 8,335 |
| Loss on disposal of and reserve adjustments for medical equipment | 337 | 678 |
| Gain on sale of medical equipment | (2,282) | (1,863) |
| Amortization of intangible assets | 709 | 743 |
| Amortization of deferred debt issuance costs | 61 | 58 |
| Stock-based compensation | 3,091 | 3,276 |
| Deferred income taxes | 2,530 | 1,383 |
| Changes in assets - (increase)/decrease: | ||
| Accounts receivable | (2,167) | (1,348) |
| Inventories | 941 | (298) |
| Other current assets | (762) | 385 |
| Other assets | 1,028 | 1,137 |
| Changes in liabilities - (decrease)/increase: | ||
| Accounts payable and other liabilities | (133) | (1,229) |
| NET CASH PROVIDED BY OPERATING ACTIVITIES | 17,282 | 12,528 |
| INVESTING ACTIVITIES | ||
| Acquisition of business | (1,412) | — |
| Purchase of medical equipment | (5,341) | (12,162) |
| Purchase of property and equipment | (427) | (562) |
| Proceeds from sale of medical equipment, property and equipment | 2,582 | 2,754 |
| NET CASH USED IN INVESTING ACTIVITIES | (4,598) | (9,970) |
| FINANCING ACTIVITIES | ||
| Principal payments on long-term debt | (44,265) | (40,415) |
| Cash proceeds from long-term debt | 41,502 | 39,231 |
| Debt issuance costs | (230) | — |
| Common stock repurchased as part of share repurchase program | (8,563) | (981) |
| Common stock repurchased to satisfy statutory withholding on employee stock-based compensation plans | (1,036) | (625) |
| Cash proceeds from exercise of options and ESPP | 336 | 381 |
| NET CASH USED IN FINANCING ACTIVITIES | (12,256) | (2,409) |
| Net change in cash and cash equivalents | 428 | 149 |
| Cash and cash equivalents, beginning of period | 527 | 231 |
| Cash and cash equivalents, end of period | $955 | $380 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.